Qingdao Saber Technology Pharmaceutical (revision 34)

Qingdao Saber Technology Pharmaceutical (trading as QST; qingdaosabertechnology.com) is a research-compound supplier trading as QST from Qingdao, Shandong, China, incorporated in 2017, supplying research peptides, SARMs and raw materials with batch documentation.^[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in 2017 in Qingdao, the organisation is one of two covered here based in that city, the other being Qingdao Sigma Chemical.^[1] Qingdao has a substantial chemical and pharmaceutical-intermediate sector and a major port, which is the extent of what can reliably be said about the industrial context.

Its registered name includes "Pharmaceutical", which places the registration closer to its trading activity than several comparators. That is a registry fact and not an indication of regulatory status: registration in a pharmaceutical business scope is not a manufacturing authorisation and confers no quality assurance.^[1]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe lyophilised material in crimped vials with a batch certificate reporting purity and appearance. Water figures have appeared inconsistently across the submitted set.^[5] Packaging descriptions have been conventional, with a gel pack on the temperature-sensitive lines.

No certification claim has been corroborated, and the organisation's own statements about capability are self-published.^[2][6]

The catalogue follows the sector pattern. Documentation is better on the peptide lines than the bulk lines, as on most of these articles.^[5]

Submitted reports on QST material to July 2026 are fewer than for the larger entries, reflecting a smaller reported customer base rather than a quality finding.^[5] Reported area percent figures have been high in most cases.

One report in the set concerned a vial whose contents did not reconstitute to a clear solution. Visible particulate or incomplete dissolution is an appearance failure that a purity figure obtained on the dissolved fraction will not reveal, since the assay measures what went into the injector.^[7] A single report establishes nothing about the organisation and is recorded because the failure mode is one readers should know to look for.

The PeptidePedia tally records 668 self-reported submissions to July 2026 — below the median for these articles. Recurring complaints concern documentation consistency; recurring positive themes are price and delivery.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][7]

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.